Events
Understanding the new pharmacy procurement induction programme
Launch of the SPS pharmacy procurement induction programme, its purpose, use, and a demonstration. For procurement staff and education & senior pharmacy leads.
Corrective and preventive actions in aseptic services
An SPS Quality Assurance (QA) bite size learning event on corrective and preventive actions (CAPA) in aseptic services.
Spotlight, September 2025
A digest of NHS Specialist Pharmacy Service support for professionals working in all areas of the healthcare system for September 2025.
Past Events
Search our library of past events for recordings, presentations, and interviews with speakers, all to inform your practice.
New Guidance
New articles published to the website during September 2025.
Biosimilars
Preparing to use omalizumab biosimilar
Omalizumab biosimilars are expected soon. We offer general information and implementation advice.
Restricted to NHS: The licence and supporting evidence for aflibercept biosimilars
Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences.
Enteral feeding tubes
How enteral feeding tubes affect medicines
Overview of enteral feeding tubes, medicine selection, feed interactions, administration techniques, and managing tube blockages.
Medicines Procurement
Rarely used medicines – How to view them on RxInfo
A guide to support on-call staff in locating supplies of rarely used medicines out of hours.
Updated Guidance
Articles updated for September 2025.
Biosimilars
Understanding biosimilar and generic market entry
New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.
Preparing to use denosumab 60mg biosimilar
Biosimilars of denosumab 60mg (Prolia) are expected soon. We offer general information and implementation advice.
Preparing to use aflibercept 2mg biosimilar
Aflibercept 2mg biosimilars for use in ophthalmology are expected in December 2025 for NHS use. We offer general information and implementation advice.
Medication Safety
Ensuring time critical use of rasburicase
Timely use of rasburicase for treatment of tumour lysis syndrome is essential. Mitigation strategies can minimise harm associated with delayed therapy.
Medicines Monitoring
A full update, which comprises a comprehensive literature review and content verification, has been completed for:
Shortages
Prescribing available HRT products
Hormone Replacement Therapy availability varies currently. Check for available products and keep up-to-date. Supply content is maintained regularly by DHSC.
Medicines Supply Tool
Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates. Content provided by DHSC and MVA team, NHS England.